能倍乐对合并前列腺肥大的慢性阻塞性肺疾病急性加重的影响

doi:10.3969/j.issn.1000-8535.2020.03.017

广州医药 ›› 2020, Vol. 51 ›› Issue (3): 73-76.DOI: 10.3969/j.issn.1000-8535.2020.03.017

能倍乐对合并前列腺肥大的慢性阻塞性肺疾病急性加重的影响

李晓岩¹, 陈豫钦², 莫泽珣¹, 何桦¹, 张歆¹, 唐万娜¹, 谭锦文¹

1 广州市第一人民医院,华南理工大学附属第二医院(广州 510180)
2 广州医科大学呼吸健康研究院呼吸疾病国家重点实验室(广州 510180)

收稿日期:2019-10-25 出版日期:2020-05-20 发布日期:2021-11-28

Effect of Spiriva Respimat on acute exacerbation of chronic obstructive pulmonary disease with benign prostatic hyperplasia

LI Xiaoyan¹, CHEN Yuqin², MO Zexun¹, HE Hua¹, ZHANG Xin¹, TANG Wanna¹, TAN Jinwen¹

1 Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology,Guangzhou 510180,China
2 State Key Laboratory of Respiratory Diseases, Respiratory Health Research Institute, Guangzhou Medical University,Guangzhou 510120,China

Received:2019-10-25 Online:2020-05-20 Published:2021-11-28

摘要/Abstract

摘要： 目的探讨噻托溴铵喷雾剂(能倍乐)对合并有前列腺肥大(BPH)的慢性阻塞性肺疾病急性加重的影响。方法 2017年9月—2019年9月在我院呼吸与危重症医学科的AECOPD的男性患者167例,年龄51～96岁,平均(74.26±7.6)岁。分别为AECOPD组、AECOPD+噻托溴铵喷雾剂治疗组。比较AECOPD合并BPH与能倍乐的关系。结果 AECOPD患者合并有BPH的45人(52.94%),能倍乐治疗合并有BPH的AECOPD患者48人(58.53%),两组比较差异无统计学意义(P＞0.05)。其中,AECOPD患者合并有BPH患者中有10人(11.76%)出现尿频、夜尿多;尿潴留的4人(4.7%);同时口服哈乐和保列治的16人(18.82%);要置尿管导尿的5人(5.8%)。能倍乐治疗AECOPD患者合并有BPH患者中有7人(8.53%)出现尿频、夜尿多;尿潴留的1人(1.21%);同时口服哈乐和保列治的20人(24.39%);要置尿管导尿的3人(3.6%),比较差异均无统计学意义(P＞0.05)。结论能倍乐不增加合并BPH的COPD患者的急性加重;也不增加治疗BPH的药物使用。能倍乐对于稳定期合并BPH的COPD患者治疗是安全的。

关键词: 慢性阻塞性肺疾病急性加重(AECOPD), 前列腺肥大(BPH), 噻托溴铵喷雾剂(能倍乐)

Abstract: Objective To investigate the effect of Spiriva Respimat on acute exacerbation of COPD with benign prostatic hyperplasia(BPH). Methods The 167 patients who were hospitalized for acute exacerbation of chronic obstructive pulmonary disease (COPD)(aged 51～96 years) with an average age of (74.26±7.6) years and the 82 patients treated with Spiriva Respimat in the department of respiratory and critical care medicine of our hospital from September 2017 to September 2019 were reviewed. In our pilot study, 48 AECOPD patients with BPH patients were enrolled as the treatment group and another 45 similar cases as the control group. In the former group Spiriva Respimat was administered and the control group was not. Results There were 45 patients (52.94%) with BPH in AECOPD group and 48 patients (58.53%) with BPH in Spiriva Respimat group. There was no statistical significance between the two groups (P>0.05). Among them, 10 patients (11.76%) with AECOPD and BPH had frequent urination and night urination, 4 patients (4.7%) of urinary retention, 16 patients (18.82%) who had oral Harnal and Finasteride, 5 patients (5.8%) need catheterization. In the AECOPD patients with BPH treated with Spiriva Respimat, 7 patients (8.53%) had frequent urination and night urination, 1 patient (1.21%) had urinary retention, 20 patients (24.39%) had oral Harnal and Finasteride, and 3 patients (3.6%) were managed through catheterization (P>0.05). Conclusion Spiriva Respimat does not increase the acute exacerbation of COPD patients with BPH, nor does it increase the use of drugs to treat BPH. It is safe to treat COPD patients with BPH in stable stage.

Key words: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD), Benign prostatic hyperplasia (BPH), Spiriva Respimat

李晓岩, 陈豫钦, 莫泽珣, 何桦, 张歆, 唐万娜, 谭锦文. 能倍乐对合并前列腺肥大的慢性阻塞性肺疾病急性加重的影响[J]. 广州医药, 2020, 51(3): 73-76.

LI Xiaoyan, CHEN Yuqin, MO Zexun, HE Hua, ZHANG Xin, TANG Wanna, TAN Jinwen. Effect of Spiriva Respimat on acute exacerbation of chronic obstructive pulmonary disease with benign prostatic hyperplasia[J]. Guangzhou Medical Journal, 2020, 51(3): 73-76.

参考文献

[1] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis,managemennt,andprevention of COPD:2016[EB/OL]. (2016-06-22)[2019-09-10] http://www.goldcopd.org/guidelines-globalstrategy-for-diagnosis-management.html.
[2] SINGH S,FURBERG C D. Inhaled anticholinergics for chronic obstructive pulmonary disease:comment on“inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease”[J]. Arch Intern Med,2011,171(10):920-922.
[3] 赵丽敏,马利军,吴纪珍,等. 老年良性前列腺增生与慢性阻塞性肺疾病的关系[J]. 中国老年学杂志,2012,32(24):5415-5416.
[4] MUNIYAPPA R,LEE S,CHEN H,et al. Current approaches for assessing insulin sensitivity and resistance in vivo:advantages,limitations,and appropriate usage[J]. Am J Physiol Endocrinol Metab,2008,294(1):E15-E26.
[5] ALATRASH A, MEHRI R, OGRODNIK N, et al. Experimental study of spiriva respimat soft mist inhaler spray characterization: size distributions and velocity[J]. Aerosol Med Pulm Drug Deliv, 2019,32(5):293-302.
[6] LUIGINO C, PAOLA R, CLIVE P, et al. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways[J]. Pulm Pharmacol Ther,2019,3(4):1010-1016.
[7] 果宏峰,那彦群.《良性前列腺增生诊断治疗指南》解读及相关研究进展[J]. 现代实用医学, 2014, 26(10): 1193-1195.
[8] TANG Y, MASSEY D, ZHONGN S.Evaluation of the efficacy and safety of tiotropium bromide(5μg)inhaled via Respimatin Chinese patients with chronic obstructive pulmonary disease[J]. Chin Med J (Engl),2013, 126(19):3603-3607.
[9] JAMES F D, JAN A van N, ERIC D B, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol[J]. Chest, 2002,1(122):47-55.
[10] 蔡华丹,侯均, 吕永宁,等. 噻托溴铵喷雾剂治疗慢性阻塞性肺疾病的有效性与安全性荟萃分析[J]. 中华结核和呼吸杂志,2017,40(8): 596-603.
[11] 赵丽敏,马利军,吴纪珍,等. 老年良性前列腺增生与慢性阻塞性肺疾病的关系[J]. 中国老年学杂志,2012,32(24):5415-5416.

能倍乐对合并前列腺肥大的慢性阻塞性肺疾病急性加重的影响

Effect of Spiriva Respimat on acute exacerbation of chronic obstructive pulmonary disease with benign prostatic hyperplasia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价